非小细胞肺癌的磷酸化EGFR与EGFR基因突变的比较分析
|
摘要
肺癌已成为导致死亡的最主要的恶性肿瘤,尽管治疗方法有所改进,但是肺癌的5年生存率并没有得到明显的改善。肺癌中非小细胞肺癌(non-small cell lung cancer NSCLC)比率为80%,大部分NSCLC很早就有远处转移,平均生存期比较短。
表皮生长因子受体(epidermal growth factor receptor,EGFR)是分子量为170kDa的酪氨酸激酶,含有一个胞外配体结合结构,一个跨膜结构和一个具有酪氨酸激酶活性的胞浆结构。EGFR信号转导途径在肿瘤细胞的增殖、细胞凋亡、新生血管形成、细胞粘附力和活性有关,而且对肿瘤进展起到非常重要的作用。EGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitor TKI)具有显著的抗肿瘤作用。现已证实EGFR的基因突变可作为预测对EGFR-TKI疗效敏感的指标,已经发现EGFR-TKI的治疗疗效与性别、病理类型及吸烟史相关。
EGFR基因突变的检测是通过PCR和基因测序方法,该方法操作复杂,无法作为日常临床中的常规检查。有研究发现在EGFR-TKI敏感的细胞株发生EGFR磷酸化,EGFR的磷酸化水平在野生型和突变型中的比较具有差异。目前关于EGFR基因突变与磷酸化EGFR关系的研究较少,国内尚无研究报道。
本研究目的检测NSCLC磷酸化EGFR与EGFR基因突变及临床特征的关系。在130例手术切除的NSCLC中用免疫组化方法检测EGFR和EGFR 2个酪氨酸磷酸化位点(pEGFR-tyr1045和pEGFR-tyr1068)的表达,并采用PCR扩增和基因测序检测EGFR基因突变情况,研究磷酸化EGFR与EGFR基因突变及临床特征的关系。结果发现EGFR基因突变与性别、病理类型和吸烟史有关,而且pEGFR-tyr1045和pEGFR-tyr1068与EGFR基因突变有关,pEGFR-tyr1045和pEGFR-tyr1068能够预测EGFR基因突变情况,可以预测EGFR-TKI治疗疗效。
Background: Lung cancer has become the most common cause of cancer death. Despite strong therapeutic efforts, the overall 5-year survival rate of patients with lung cancer is only 15% without having improved over the last 30 years. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancers, NSCLC is thought to originate in lung epithelial cells, and comprises diverse histological subtypes including adenocarcinoma, bronchioloalveolar, squamous and large-cell carcinomas. Most patients with advanced NSCLC present with metastatic disease and, if left untreated, have a median survival after diagnosis of 4-5 months and a year survival of less than 10%.
EGFR is a 170 kDa tyrosine kinase receptor consisting of an extracellular domain, a transmembrane domain, and a cytoplasmic domain comprised of the tyrosine kinase domain. Ligand binding results in receptor dimerization, autophosphorylation of specific tyrosine residues, and activation of downstream signaling. The EGFR signal regulates proliferation, apoptosis, angiogenesis, cell adhesion, and motility, and therefore the receptor has a great impact on tumour growth and progression.
EGFR is an important target for cancer therapy, these mutations endow the receptor with ligand-independent catalytic activity and are oncogenic in a number of model systems. Most tumors harboring EGFR kinase domain mutations are dependent on them as EGFR tyrosine kinase inhibitors induce a marked antitumor effect.
Gefitinib has been widely used in the treatment of NSCLC as tyrosine kinase inhibitor (EGFR-TKI). To date, EGFR mutation has been thought to be the most sensitive predictor of gefitinib response and is correlated with gender, histology and smoking history. The observation of higher response rates with EGFR-TKI in selected groups of patients, as well as the disappointing results with EGFR-TKI in unselected patients, it is very important to study the potential predictive value in patients treated with EGFR-TKI.
Studies have showed that gefitinib was effective in 80-90% of patients with EGFR mutations, and in 10-20% of patients with wild-type EGFR. If we rely solely on gene mutation in gefitinib treatment as predictor, will make part of patients who respond to gefitinib missed opportunities. So screening for the treatment of EGFR-TKI-sensitive patients is particularly important, although the gene mutation as the current predictor of EGFR-TKI treatment, but still need to improve. In a recent study, found that about half of the tumor of lung cancer have expression of EGFR phosphorylation, EGFR phosphorylation, not only in the expression of EGFR mutations in lung cancer, but also exist in the wild-type EGFR of lung tumor. Some studies found that the level of phosphorylation of the EGFR mutant cell line was comparable with the level of phosphorylation in wild-type cells.
Objective: To study the correlation between phosphorylated EGFR and EGFR mutation in resected non-small cell lung cancers.
Methods: DNAs were extracted from 130 cases paraffin embedded NSCLC tissues and the exon 18, 19, 21 of EGFR were sequenced to detect the EGFR mutation status; the expression of EGFR and phosphorylated EGFR at tyrosine 1045 and 1068 (pEGFR-tyr1045 and pEGFR-tyr1068) were also studied in total 130 cases NSCLC by immuohistochemical method. Examined the correlations between EGFR mutation and phosphorylated EGFR..
Results: EGFR mutation (Exon 18,19,21) were seen in 29.2% (38/130) of 130 NSCLCs, In adenocarcinoma, 38.7% (29/75) of patients had EGFR mutation. 21.3% (17/80) of males and 42.0% (21/50) of females had EGFR mutation. 40.3% (25/62) of patients who had never smoked and 19.1% (13/68) of smokers had the EGFR mutation. Furthermore, adenocarcinoma, female and non-smoking were significantly correlated to the EGFR mutations (P<0.05). There is no correlations were found between EGFR mutations and patient’s age, tumor size, nodal status, and clinical stage (P>0.05).
Expression of EGFR were positive in 67.7% (88/130) of all patients, 78.9% (30/38) of patients had EGFR mutation , 76.0% (38/50) of females ,72.0% (54/75) of patients with adenocarcinoma , and 74.2%(46/62)of patients who had never smoked were positive of EGFR expression. No correlations were found between EGFR expression and these characteristics(P>0.05), But EGFR expression was correlated to pEGFR-tyr1045 and pEGFR-tyr1068 (P<0.05).
Expression of pEGFR-tyr1045 were positive in 51.5% (67/130) of patients, 73.7%(28/38) of patients had EGFR mutation, 64.0%(32/50)of females, and 64.0% (48/75) of patients with adenocarcinoma were pEGFR-tyr1045 positive, the correlations between pEGFR- tyr1045 and these characteristics were significant(P<0.05).
Expression of pEGFR-tyr1068 were positive in 55.4% (72/130) of patients, 76.3%(29/38) of patients had EGFR mutation, 70.0%(35/50)of females, and 66.7%(50/75)of patients with adenocarcinoma, 64.5%(40/62)of patients who had never smoked were pEGFR-tyr1068 positive, pEGFR-tyr1068 was significantly correlated with EGFR mutation, gender, histology and smoking history (P<0.05).
Conclusions: Statistical analysis of these results revealed that the presence of EGFR mutations was significantly correlated with gender, histology and smoking history, pEGFR-tyr1045 and pEGFR-tyr1068 were significantly correlated with EGFR mutation, pEGFR-tyr1045 and pEGFR-tyr1068 can predict EGFR mutation, and they may be a sensitive predictor of EGFR-TKI response.
It has been reported that some patients develop adverse effect of gefitinib treatment, therefore, careful judgment in balancing the potential benefits and toxicity is required, and a useful method for predicting the responsiveness to EGFR-TKI has been awaited. Our immunohistochemical diagnosis of EGFR phosphorylation status at tyrosine residue 1045 and 1068 appears to have a number of advantages over mutation analysis of the EGFR gene. First, immunohistochemistry with anti–pEGFR-tyr1045 and 1068 antibody is easier to perform than mutation analysis of the EGFR gene. Second, immunohistochemistry facilitates direct identification of the tumor cells in which EGFR is phosphorylated, whereas in mutation analysis, contamination with the genomic DNA of normal cells cannot be ruled out. Third, our method is less invasive for patients, as paraffin-embedded tissue samples taken from patients for histopathologic diagnosis can be reused for immunohistochemical analysis, obviating the need for another biopsy sample for mutation analysis.
10-20% of wild-type EGFR in NSCLC cancer patients sensitive to TKI treatment, but these patients with gene mutation as an indicator of prediction gefitinib treatment, may be excluded from the treatment of TKI-sensitive patients. Although phospho-EGFR analysis might not be superior to sequence analysis as a predictive marker of TKI response, however, detection of phosphorylated EGFR can supplement the omission of screening, and immunohistochemistry of EGFR is a conveninent tool for predicting the presence of EGFR gene mutation, and can be applied to daily clinical practice examination.
表皮生长因子受体(epidermal growth factor receptor,EGFR)是分子量为170kDa的酪氨酸激酶,含有一个胞外配体结合结构,一个跨膜结构和一个具有酪氨酸激酶活性的胞浆结构。EGFR信号转导途径在肿瘤细胞的增殖、细胞凋亡、新生血管形成、细胞粘附力和活性有关,而且对肿瘤进展起到非常重要的作用。EGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitor TKI)具有显著的抗肿瘤作用。现已证实EGFR的基因突变可作为预测对EGFR-TKI疗效敏感的指标,已经发现EGFR-TKI的治疗疗效与性别、病理类型及吸烟史相关。
EGFR基因突变的检测是通过PCR和基因测序方法,该方法操作复杂,无法作为日常临床中的常规检查。有研究发现在EGFR-TKI敏感的细胞株发生EGFR磷酸化,EGFR的磷酸化水平在野生型和突变型中的比较具有差异。目前关于EGFR基因突变与磷酸化EGFR关系的研究较少,国内尚无研究报道。
本研究目的检测NSCLC磷酸化EGFR与EGFR基因突变及临床特征的关系。在130例手术切除的NSCLC中用免疫组化方法检测EGFR和EGFR 2个酪氨酸磷酸化位点(pEGFR-tyr1045和pEGFR-tyr1068)的表达,并采用PCR扩增和基因测序检测EGFR基因突变情况,研究磷酸化EGFR与EGFR基因突变及临床特征的关系。结果发现EGFR基因突变与性别、病理类型和吸烟史有关,而且pEGFR-tyr1045和pEGFR-tyr1068与EGFR基因突变有关,pEGFR-tyr1045和pEGFR-tyr1068能够预测EGFR基因突变情况,可以预测EGFR-TKI治疗疗效。
Background: Lung cancer has become the most common cause of cancer death. Despite strong therapeutic efforts, the overall 5-year survival rate of patients with lung cancer is only 15% without having improved over the last 30 years. Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancers, NSCLC is thought to originate in lung epithelial cells, and comprises diverse histological subtypes including adenocarcinoma, bronchioloalveolar, squamous and large-cell carcinomas. Most patients with advanced NSCLC present with metastatic disease and, if left untreated, have a median survival after diagnosis of 4-5 months and a year survival of less than 10%.
EGFR is a 170 kDa tyrosine kinase receptor consisting of an extracellular domain, a transmembrane domain, and a cytoplasmic domain comprised of the tyrosine kinase domain. Ligand binding results in receptor dimerization, autophosphorylation of specific tyrosine residues, and activation of downstream signaling. The EGFR signal regulates proliferation, apoptosis, angiogenesis, cell adhesion, and motility, and therefore the receptor has a great impact on tumour growth and progression.
EGFR is an important target for cancer therapy, these mutations endow the receptor with ligand-independent catalytic activity and are oncogenic in a number of model systems. Most tumors harboring EGFR kinase domain mutations are dependent on them as EGFR tyrosine kinase inhibitors induce a marked antitumor effect.
Gefitinib has been widely used in the treatment of NSCLC as tyrosine kinase inhibitor (EGFR-TKI). To date, EGFR mutation has been thought to be the most sensitive predictor of gefitinib response and is correlated with gender, histology and smoking history. The observation of higher response rates with EGFR-TKI in selected groups of patients, as well as the disappointing results with EGFR-TKI in unselected patients, it is very important to study the potential predictive value in patients treated with EGFR-TKI.
Studies have showed that gefitinib was effective in 80-90% of patients with EGFR mutations, and in 10-20% of patients with wild-type EGFR. If we rely solely on gene mutation in gefitinib treatment as predictor, will make part of patients who respond to gefitinib missed opportunities. So screening for the treatment of EGFR-TKI-sensitive patients is particularly important, although the gene mutation as the current predictor of EGFR-TKI treatment, but still need to improve. In a recent study, found that about half of the tumor of lung cancer have expression of EGFR phosphorylation, EGFR phosphorylation, not only in the expression of EGFR mutations in lung cancer, but also exist in the wild-type EGFR of lung tumor. Some studies found that the level of phosphorylation of the EGFR mutant cell line was comparable with the level of phosphorylation in wild-type cells.
Objective: To study the correlation between phosphorylated EGFR and EGFR mutation in resected non-small cell lung cancers.
Methods: DNAs were extracted from 130 cases paraffin embedded NSCLC tissues and the exon 18, 19, 21 of EGFR were sequenced to detect the EGFR mutation status; the expression of EGFR and phosphorylated EGFR at tyrosine 1045 and 1068 (pEGFR-tyr1045 and pEGFR-tyr1068) were also studied in total 130 cases NSCLC by immuohistochemical method. Examined the correlations between EGFR mutation and phosphorylated EGFR..
Results: EGFR mutation (Exon 18,19,21) were seen in 29.2% (38/130) of 130 NSCLCs, In adenocarcinoma, 38.7% (29/75) of patients had EGFR mutation. 21.3% (17/80) of males and 42.0% (21/50) of females had EGFR mutation. 40.3% (25/62) of patients who had never smoked and 19.1% (13/68) of smokers had the EGFR mutation. Furthermore, adenocarcinoma, female and non-smoking were significantly correlated to the EGFR mutations (P<0.05). There is no correlations were found between EGFR mutations and patient’s age, tumor size, nodal status, and clinical stage (P>0.05).
Expression of EGFR were positive in 67.7% (88/130) of all patients, 78.9% (30/38) of patients had EGFR mutation , 76.0% (38/50) of females ,72.0% (54/75) of patients with adenocarcinoma , and 74.2%(46/62)of patients who had never smoked were positive of EGFR expression. No correlations were found between EGFR expression and these characteristics(P>0.05), But EGFR expression was correlated to pEGFR-tyr1045 and pEGFR-tyr1068 (P<0.05).
Expression of pEGFR-tyr1045 were positive in 51.5% (67/130) of patients, 73.7%(28/38) of patients had EGFR mutation, 64.0%(32/50)of females, and 64.0% (48/75) of patients with adenocarcinoma were pEGFR-tyr1045 positive, the correlations between pEGFR- tyr1045 and these characteristics were significant(P<0.05).
Expression of pEGFR-tyr1068 were positive in 55.4% (72/130) of patients, 76.3%(29/38) of patients had EGFR mutation, 70.0%(35/50)of females, and 66.7%(50/75)of patients with adenocarcinoma, 64.5%(40/62)of patients who had never smoked were pEGFR-tyr1068 positive, pEGFR-tyr1068 was significantly correlated with EGFR mutation, gender, histology and smoking history (P<0.05).
Conclusions: Statistical analysis of these results revealed that the presence of EGFR mutations was significantly correlated with gender, histology and smoking history, pEGFR-tyr1045 and pEGFR-tyr1068 were significantly correlated with EGFR mutation, pEGFR-tyr1045 and pEGFR-tyr1068 can predict EGFR mutation, and they may be a sensitive predictor of EGFR-TKI response.
It has been reported that some patients develop adverse effect of gefitinib treatment, therefore, careful judgment in balancing the potential benefits and toxicity is required, and a useful method for predicting the responsiveness to EGFR-TKI has been awaited. Our immunohistochemical diagnosis of EGFR phosphorylation status at tyrosine residue 1045 and 1068 appears to have a number of advantages over mutation analysis of the EGFR gene. First, immunohistochemistry with anti–pEGFR-tyr1045 and 1068 antibody is easier to perform than mutation analysis of the EGFR gene. Second, immunohistochemistry facilitates direct identification of the tumor cells in which EGFR is phosphorylated, whereas in mutation analysis, contamination with the genomic DNA of normal cells cannot be ruled out. Third, our method is less invasive for patients, as paraffin-embedded tissue samples taken from patients for histopathologic diagnosis can be reused for immunohistochemical analysis, obviating the need for another biopsy sample for mutation analysis.
10-20% of wild-type EGFR in NSCLC cancer patients sensitive to TKI treatment, but these patients with gene mutation as an indicator of prediction gefitinib treatment, may be excluded from the treatment of TKI-sensitive patients. Although phospho-EGFR analysis might not be superior to sequence analysis as a predictive marker of TKI response, however, detection of phosphorylated EGFR can supplement the omission of screening, and immunohistochemistry of EGFR is a conveninent tool for predicting the presence of EGFR gene mutation, and can be applied to daily clinical practice examination.
引文
[1] PARKIN DM, BRAY F, FERLAY J, et al. Global cancer statistics, 2002. CA[J]. a cancer journal for clinicians, 2005,55:74-108.
[2] JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics, 2006. CA[J]. a cancer journal for clinicians, 2006,56:106-130.
[3] OHSAKI Y, TANNO S, FUJITA Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression[J]. Oncology reports, 2000,7: 603-607.
[4] FUJINO S, ENOKIBORI T, TEZUKA N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer[J]. Eur J Cancer, 1996,32A:2070-2074.
[5] HILBE W, DLASKA M, DIRNHOFER S, et al. Characterisation and predictive value of epidermal growth factor receptor status using quantitative real-time PCR combined with immunohistochemistry on non-small cell lung cancer specimens[J]. International journal of oncology, 2003,23:893-899.
[6] BRATTSTROM D, WESTER K, BERGQVIST M, et al. HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer[J]. Acta oncologica (Stockholm, Sweden), 2004,43:80-86.
[7] JORISSEN RN, WALKER F, POULIOT N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling[J]. Experimental cell research, 2003,284: 31-53.
[8] BASELGA J. Why the epidermal growth factor receptor? The rationale for cancer therapy[J]. The oncologist, 2002,7 Suppl 4:2-8.
[9] WOOD ER, TRUESDALE AT, MCDONALD OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells[J].Cancer research, 2004,64: 6652-6659.
[10] PAO W, MILLER VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions[J]. J Clin Oncol, 2005,23: 2556-2568.
[11] KARI C, CHAN TO, ROCHA DE QUADROS M, RODECK U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage[J]. Cancer research, 2003,63:1-5.
[12] BASELGA J, ARTEAGA CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer[J]. J Clin Oncol, 2005,23:2445-2459.
[13] YARDEN Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities[J]. Eur J Cancer, 2001,37 Suppl 4:S3-8.
[14] MCKILLOP D, PARTRIDGE EA, KEMP JV, et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor[J]. Molecular cancer therapeutics, 2005,4:641- 649.
[15] DI GENNARO E, BARBARINO M, BRUZZESE F, et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells[J]. Journal of cellular physiology, 2003,195:139-150.
[16] COHEN MH, WILLIAMS GA, SRIDHARA R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets[J]. The oncologist, 2003,8: 303-306.
[17] BISHAYEE S. Role of conformational alteration in the epidermal growth factor receptor (EGFR) function[J]. In, Biochemical pharmacology, 2000,1217-1223.
[18] RAYMOND E, LOUVET C, TOURNIGAND C, et al. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells[J]. International journal of oncology, 2002,21:361-367.
[19]李龙芸,周彩存,张国淳.非小细胞肺癌患者EGFR突变和基因扩增对吉非替尼疗效的预测价值[J].循证医学, 2006,6(1):23-27.
[20] RUOCCO S, LALLEMAND A, TOURNIER JM, et al. Expression and localization of epidermal growth factor, transforming growth factor-alpha, and localization of their common receptor in fetal human lung development[J]. Pediatric research, 1996,39: 448-455.
[21] STRANDJORD TP, CLARK JG, GURALNICK DE, et al. Immunolocalization of transforming growth factor-alpha, epidermal growth factor (EGF), and EGF-receptor in normal and injured developing human lung[J]. Pediatric research, 1995,38:851-856.
[22] FUJITA Y, KURACHI H, MORISHIGE K, et al. Decrease in epidermal growth factor receptor and its messenger ribonucleic acid levels in intrauterine growth-retarded and diabetes mellitus-complicated pregnancies[J]. The Journal of clinical endocrinology and metabolism, 1991,72:1340-1345.
[23] OGISO H, ISHITANI R, NUREKI O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains[J]. Cell, 2002,110:775-787.
[24] VERED M, BRAUNSTEIN E, BUCHNER A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin[J]. Head & neck, 2002,24:632-636.
[25] LEMOINE NR, HUGHES CM, GULLICK WJ, et al. Abnormalities of the EGF receptor system in human thyroid neoplasia[J]. International journal of cancer, 1991,49:558-561.
[26] MIETTINEN PJ, WARBURTON D, BU D, et al. Impaired lung branching morphogenesis in the absence of functional EGF receptor[J]. Developmental biology, 1997,186:224-236.
[27] KUBIAK J, MITRA MM, STEVE AR, et al. Transforming growth factor-alpha gene expression in late-gestation fetal rat lung[J]. Pediatric research, 1992,31:286-290.
[28] YASUI S, NAGAI A, OOHIRA A, et al. Effects of anti-mouse EGF antiserum on prenatal lung development in fetal mice[J]. Pediatric pulmonology, 1993,15:251-256.
[29] PLOPPER CG, ST GEORGE JA, READ LC, et al. Acceleration of alveolar type II cell differentiation in fetal rhesus monkey lung by administration of EGF[J]. The American journal of physiology, 1992,262:L313-321.
[30] PRICE LT, CHEN Y, FRANK L. Epidermal growth factor increases antioxidant enzyme and surfactant system development during hyperoxia and protects fetal rat lungs in vitro from hyperoxic toxicity[J]. Pediatric research, 1993,34:577-585.
[31] LU Z, JIANG G, BLUME-JENSEN P, et al. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase[J]. Molecular and cellular biology, 2001,21:4016-4031.
[32] JOHANNESSEN LE, RINGERIKE T, MOLNES J, et al. Epidermal growth factor receptor efficiently activates mitogen-activated protein kinase in HeLa cells and Hep2 cells conditionally defective in clathrin- dependent endocytosis[J]. Experimental cell research, 2000,260: 136-145.
[33] BERGSTROM JD, WESTERMARK B, HELDIN NE. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells[J]. Experimental cell research, 2000,259:293-299.
[34] DENNING MF, DLUGOSZ AA, CHENG C, et al. Cross-talk between epidermal growth factor receptor and protein kinase C during calcium-induced differentiation of keratinocytes[J]. Experimental dermatology, 2000, 9:192-199.
[35] ONO M, KUWANO M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs[J]. Clin Cancer Res, 2006,12:7242-7251.
[36] OLAYIOYE MA, NEVE RM, LANE HA, et al. The erbB signaling network: receptor heterodimerization in development and cancer[J]. The EMBO journal, 2000,19:3159-3167.
[37] RABEN D, HELFRICH B, BUNN PA, et al. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncologyperspective[J]. International journal of radiation oncology, biology, physics, 2004,59:27-38.
[38] LEI W, MAYOTTE JE, LEVITT ML. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells[J]. Anticancer research, 1999,19:221-228.
[39] WAKELING AE, GUY SP, WOODBURN JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy[J]. Cancer research, 2002,62: 5749-5754.
[40] SAITO Y, BERK BC. Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors[J]. Journal of molecular and cellular cardiology, 2001,33:3-7.
[41] PAEZ JG, JANNE PA, LEE JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[J]. Science (New York, NY, 2004,304:1497-1500.
[42] LYNCH TJ, BELL DW, SORDELLA R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. The New England journal of medicine, 2004,350:2129-2139.
[43] SCAGLIOTTI GV, SELVAGGI G, NOVELLO S, et al. The biology of epidermal growth factor receptor in lung cancer[J]. Clin Cancer Res, 2004,10: 4227s-4232s.
[44] RUSCH V, BASELGA J, CORDON-CARDO C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung[J]. Cancer research, 1993,53:2379-2385.
[45] CERNY T, BARNES DM, HASLETON P, et al. Expression of epidermal growth factor receptor (EGF-R) in human lung tumours[J]. British journal of cancer, 1986,54:265-269.
[46] RUSCH V, KLIMSTRA D, LINKOV I, et al. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development[J]. Cancer research,1995,55:1365-1372.
[47] REISSMANN PT, KOGA H, FIGLIN RA, et al. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer[J]. Lung Cancer Study Group. Journal of cancer research and clinical oncology, 1999,125:61-70.
[48] VOLM M, RITTGEN W, DRINGS P. Prognostic value of erbB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas[J]. British journal of cancer, 1998,77:663-669.
[49] DICKSTEIN BM, WOSIKOWSKI K, BATES SE. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor[J]. Molecular and cellular endocrinology, 1995,110:205-211.
[50] SKIMISDOTTIR S, HREGGVIDSSON GO, HOLST O, et al. A new ecological adaptation to high sulfide by a Hydrogenobacter sp[J]. growing on sulfur compounds but not on hydrogen. Microbiological research, 2001,156:41-47.
[51] HARLOZINSKA A, BAR JK, SOBANSKA E, et al. Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms[J]. Tumour Biol, 1998,19:364-373.
[52] CIARDIELLO F, BIANCO R, DAMIANO V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225[J]. Clin Cancer Res, 1999,5: 909-916.
[53] CILEDAG A, KAYA A, YETKIN O, et al. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer[J]. Tuberkuloz ve toraks, 2008,56:390-395.
[54] TSUTSUI S, OHNO S, MURAKAMI S, et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer[J]. Breast cancer research and treatment, 2002,71:67-75.
[55] JACOT W, PUJOL JL, BOHER JM, et al. Serum EGF-receptor and HER-2extracellular domains and prognosis of non-small-cell lung cancer[J]. British journal of cancer, 2004,91:430-433.
[56] CAPPUZZO F, HIRSCH FR, ROSSI E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer[J]. Journal of the National Cancer Institute, 2005,97:643-655.
[57] GAZDAR AF, SHIGEMATSU H, HERZ J, et al. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers[J]? Trends in molecular medicine, 2004,10:481-486.
[58] MILAS I, KOMAKI R, HACHIYA T, et al. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases[J]. Clin Cancer Res, 2003,9: 1070-1076.
[59] NICHOLSON RI, GEE JM, HARPER ME. EGFR and cancer prognosis[J]. Eur J Cancer, 2001,37 Suppl 4:S9-15.
[60] BRABENDER J, DANENBERG KD, METZGER R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival[J]. Clin Cancer Res, 2001,7:1850-1855.
[61] FONTANINI G, VIGNATI S, BIGINI D, et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype[J]. Eur J Cancer, 1995,31A: 178-183.
[62] CLARKE LE, LEITZEL K, SMITH J, et al. Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR[J]. International journal of oncology, 2003,22:425-430.
[63] BLAGOSKLONNY MV. Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers[J]. Cancer biology & therapy, 2004, 3:436-440.
[64] DAS AK, CHEN BP, STORY MD, et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma[J]. Cancer research, 2007,67:5267-5274.
[65] HUMPHREY PA, GANGAROSA LM, WONG AJ, et al. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function[J]. Biochemical and biophysical research communications, 1991,178:1413-1420.
[66] MOSCATELLO DK, MONTGOMERY RB, SUNDARESHAN P, et al. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor[J]. Oncogene, 1996,13:85-96.
[67] OMIDFAR K, RASAEE MJ, MODJTAHEDI H, et al. Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus[J]. Tumour Biol, 2004,25:179-187.
[68] MOSCATELLO DK, HOLGADO-MADRUGA M, EMLET DR, et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor[J]. The Journal of biological chemistry, 1998,273:200-206.
[69] OLAPADE-OLAOPA EO, MOSCATELLO DK, MACKAY EH, et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer[J]. British journal of cancer, 2000,82:186-194.
[70] SEQUIST LV. First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients[J]. J Thorac Oncol, 2008,3:S143-145.
[71] TSUCHIHASHI Z, KHAMBATA-FORD S, HANNA N, et al. Responsiveness to cetuximab without mutations in EGFR[J]. The New England journal of medicine, 2005,353:208-209.
[72] SHIGEMATSU H, LIN L, TAKAHASHI T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers[J]. Journal of the National Cancer Institute, 2005,97:339-346.
[73] REINMUTH N, JAUCH A, XU EC, et al. Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, erbB3 and VEGF in tumor samplesof lung adenocarcinoma patients[J]. Lung cancer (Amsterdam, Netherlands), 2008,62:193-201.
[74] SHARMA SV, BELL DW, SETTLEMAN J, et al. Epidermal growth factor receptor mutations in lung cancer[J]. Nature reviews, 2007,7: 169-181.
[75] GERDES AM, NIELSEN O, MOHR U, et al. Correlation between molecular genetic analyses and immunohistochemical evaluation of the epidermal growth factor receptor and p185HER2[J]. Anticancer research, 1998, 18:2529-2534.
[76] SHIGEMATSU H, TAKAHASHI T, NOMURA M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas[J]. Cancer research, 2005,65: 1642-1646.
[77] MENDELSOHN J, BASELGA J. The EGF receptor family as targets for cancer therapy[J]. Oncogene, 2000,19:6550-6565.
[78] GREULICH H, CHEN TH, FENG W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants[J]. PLoS medicine, 2005,2:e313.
[79] KALIKAKI A, KOUTSOPOULOS A, TRYPAKI M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC[J]. British journal of cancer, 2008,99:923-929.
[80] KOBAYASHI S, BOGGON TJ, DAYARAM T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J]. The New England journal of medicine, 2005,352:786-792.
[81] NORO R, GEMMA A, KOSAIHIRA S, et al. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of AKT without ligand stimulation[J]. BMC cancer, 2006,6:277.
[82] HOTTA K, KIURA K, TABATA M, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group[J]. Cancer journal Sudbury, Mass, 2005,11:417-424.
[83] CELLA D, HERBST RS, LYNCH TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial[J]. J Clin Oncol, 2005,23:2946-2954.
[84] KRIS MG, NATALE RB, HERBST RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial[J]. Jama, 2003,290:2149-2158.
[85] HERBST RS, MADDOX AM, ROTHENBERG ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial[J]. J Clin Oncol, 2002,20:3815-3825.
[86] RANSON M, HAMMOND LA, FERRY D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial[J]. J Clin Oncol, 2002,20:2240-2250.
[87] NAKAGAWA K, TAMURA T, NEGORO S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors[J]. Ann Oncol, 2003,14:922-930.
[88] BASELGA J, RISCHIN D, RANSON M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types[J]. J Clin Oncol, 2002,20:4292-4302.
[89] GOSS G, HIRTE H, MILLER WH, et al. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group[J]. Investigational new drugs, 2005,23:147-155.
[90] NISHIWAKI Y, YANO S, TAMURA T, et al. [Subset analysis of data in the Japanesepatients with NSCLC from IDEAL 1 study on gefitinib] [J]. Gan to kagaku ryoho, 2004,31:567-573.
[91] FUKUOKA M, YANO S, GIACCONE G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] [J]. J Clin Oncol, 2003,21:2237-2246.
[92] KITAZAKI T, FUKUDA M, SODA H, et al. Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma, two case reports[J]. Lung cancer (Amsterdam, Netherlands), 2005,49:125-128.
[93] HERBST RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients[J]. Seminars in oncology, 2003,30:30-38.
[94] LORUSSO PM, HERBST RS, RISCHIN D, et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors[J]. Clin Cancer Res, 2003,9:2040-2048.
[95] GIACCONE G, HERBST RS, MANEGOLD C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1[J]. J Clin Oncol, 2004,22:777- 784.
[96] HERBST RS, GIACCONE G, SCHILLER JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2[J]. J Clin Oncol, 2004,22:785- 794.
[97] MITSUDOMI T, KOSAKA T, YATABE Y. Biological and clinical implications of EGFR mutations in lung cancer[J]. International journal of clinical oncology / Japan Society of Clinical Oncology, 2006,11: 190-198.
[98] CUFER T, VRDOLJAK E, GAAFAR R, et al. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer[J]. Anti-cancer drugs, 2006,17:401-409.
[99] TSUBOI M, KATO H, NAGAI K, et al. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer[J]. Anti-cancer drugs, 2005,16:1123-1128.
[100] SAGARA R, KITAMI A, NAKADA T, et al. Adverse reactions to gefitinib (Iressa): revealing sycosis and pyoderma gangrenosum-like lesions[J]. International journal of dermatology, 2006,45:1002 -1003.
[101] SANDLER AB. Nondermatologic adverse events associated with anti-EGFR therapy[J]. Oncology Williston Park, NY, 2006,20:35-40.
[102] LENZ HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events[J]. Oncology Williston Park, NY, 2006,20:5-13.
[103] CERSOSIMO RJ. Gefitinib: an adverse effects profile[J]. Expert opinion on drug safety, 2006,5:469-479.
[104] FUJIWARA Y, KIURA K, TOYOOKA S, et al. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer[J]. Lung cancer (Amsterdam, Netherlands), 2006,52:99-103.
[105] GIRARD N, GERINIERE L, BLANDIN S, et al. [French experience of gefitinib in non-small cell bronchial carcinoma. [J]. Revue des maladies respiratoires, 2004,21:934-942.
[106] KANEDA H, TAMURA K, KURATA T, et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer[J]. Lung cancer (Amsterdam, Netherlands), 2004,46:247-254.
[107] TAKAMOCHI K, SUZUKI K, BASHAR AH, et al. Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report[J]. Journal of medical case reports, 2007,1:138.
[108] ENDO M, JOHKOH T, KIMURA K, et al. Imaging of gefitinib-related interstitial lungdisease: multi-institutional analysis by the West Japan Thoracic Oncology Group[J]. Lung cancer (Amsterdam, Netherlands), 2006,52:135-140.
[109] TICHELAAR JW, LU W, WHITSETT JA. Conditional expression of fibroblast growth factor-7 in the developing and mature lung[J]. The Journal of biological chemistry, 2000,275:11858-11864.
[110] SORDELLA R, BELL DW, HABER DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways[J]. Science New York, NY, 2004,305: 1163-1167.
[111] SHARPLESS NE, DEPINHO RA. The INK4A/ARF locus and its two gene products[J]. Current opinion in genetics & development, 1999,9:22- 30.
[112] ROCCO JW, SIDRANSKY D. p16(MTS-1/CDKN2/INK4a) in cancer progression[J]. Experimental cell research, 2001,264:42-55.
[113] WISTUBA, II, GAZDAR AF, MINNA JD. Molecular genetics of small cell lung carcinoma[J]. Seminars in oncology, 2001,28:3-13.
[114] ONO A, YAMAMOTO N. [Advances in chemotherapy for lung cancer] [J]. Gan to kagaku ryoho, 2008,35:1475-1481.
[115] PITARCH G, GARDE J, TORRIJOS A, et al. [Adverse cutaneous reactions to erlotinib] [J]. Actas dermo-sifiliograficas, 2008,99:54-60.
[116] LACOUTURE ME, MELOSKY BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology- oncology perspective[J]. Skin therapy letter, 2007,12:1-5.
[117] KWAK EL, SORDELLA R, BELL DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005,102:7665-7670.
[118] LI T, LING YH, GOLDMAN ID, et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells[J]. Clin Cancer Res, 2007,13:3413-3422.
[119] CULLEN M. Second-line treatment options in advanced non-small cell lung cancer: current status[J]. Seminars in oncology, 2006,33:S3-8.
[120] CAPPUZZO F, LIGORIO C, JANNE PA, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization- positive/phospho- AKT-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial[J]. J Clin Oncol, 2007,25:2248-2255.
[121] KIM KS, JEONG JY, KIM YC, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer[J]. Clin Cancer Res, 2005,11:2244-2251.
[122] HIRSCH FR, VARELLA-GARCIA M, BUNN PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis[J]. J Clin Oncol, 2003,21:3798-3807.
[123] SHEPHERD FA, TSAO MS. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy[J]. J Clin Oncol, 2006,24: 1219-1220, author reply 1220-1211.
[124] KISHI K, NAKATA K, YOSHIMURA K. Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis[J]. J Thorac Oncol, 2006,1: 733-734.
[125] HAN SW, HWANG PG, CHUNG DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer[J]. International journal of cancer, 2005,113:109-115.
[126] PARRA HS, CAVINA R, LATTERI F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer[J]. British journal of cancer, 2004,91:208-212.
[127] PAO W, MILLER VA, POLITI KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J]. PLoS medicine, 2005,2:e73.
[128] CAPPUZZO F, GREGORC V, ROSSI E, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC[J]. J Clin Oncol, 2003,21:2658-2663.
[129] MITSUDOMI T, KOSAKA T, ENDOH H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence[J]. J Clin Oncol, 2005,23:2513-2520.
[130] MU XL, LI LY, ZHANG XT, et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer[J]. Clin Cancer Res, 2005,11:4289-4294.
[131] TARON M, ICHINOSE Y, ROSELL R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas[J]. Clin Cancer Res, 2005,11: 5878-5885.
[132] ZHU JQ, ZHONG WZ, ZHANG GC, et al. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals[J]. Cancer letters, 2008,265:307-317.
[133] INOUE A, SUZUKI T, FUKUHARA T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations[J]. J Clin Oncol, 2006,24:3340-3346.
[134] SUTANI A, NAGAI Y, UDAGAWA K, et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp[J]. British journal of cancer, 2006,95:1483-1489.
[135] ASAHINA H, YAMAZAKI K, KINOSHITA I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factorreceptor mutations[J]. British journal of cancer, 2006,95:998-1004.
[136] TAMURA K, OKAMOTO I, KASHII T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) [J]. British journal of cancer, 2008,98:907-914.
[137] KOSAKA T, YATABE Y, ENDOH H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib[J]. Clin Cancer Res, 2006,12:5764-5769.
[138] SEQUIST LV, JOSHI VA, JANNE PA, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing[J]. The oncologist, 2007,12:90-98.
[139] PAO W, MILLER V, ZAKOWSKI M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib[J]. Proceedings of the National Academy of Sciences of the United States of America, 2004,101:13306-13311.
[140] SHIMAMURA T, LI D, JI H, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance[J]. Cancer research, 2008,68: 5827-5838.
[141] Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib[J]. Proceedings of the National Academy of Sciences of the United States of America, 2007,104: 20932-20937.
[142] INUKAI M, TOYOOKA S, ITO S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer[J]. Cancer research, 2006,66:7854-7858.
[143] JANCARIKOVA D, PESEK M, BENESOVA L, et al. Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFRmutation T790M[J]. Anticancer research, 2007,27:1879- 1882.
[144] BELL DW, GORE I, OKIMOTO RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR[J]. Nature genetics, 2005,37:1315-1316.
[145] PAPAIAHGARI S, ZHANG Q, KLEEBERGER SR, et al. Hyperoxia stimulates an Nrf2-ARE transcriptional response via ROS-EGFR-PI3K-AKT/ERK MAP kinase signaling in pulmonary epithelial cells[J]. Antioxidants & redox signaling, 2006,8:43-52.
[146] LIU F, JIANG B, GONG SJ, et al. [Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer] [J]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 2007,24:31-34.
[147] HIRSCH FR. K-ras mutations in lung cancer: the "mysterious mutation"[J]. Clinical lung cancer, 2006,8:11-12.
[148] SUZUKI T, NAKAGAWA T, ENDO H, et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status[J]. Lung cancer (Amsterdam, Netherlands), 2003,42: 35-41.
[149] HUNCHAREK M, MUSCAT J, GESCHWIND JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases[J]. Carcinogenesis, 1999,20:1507-1510.
[150] PAO W, WANG TY, RIELY GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS medicine, 2005,2:e17.
[151] KOSAKA T, YATABE Y, ENDOH H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications[J]. Cancer research, 2004,64:8919-8923.
[152] GU D, SCARINGE WA, LI K, et al. Database of somatic mutations in EGFR withanalyses revealing indel hotspots but no smoking-associated signature[J]. Human mutation, 2007,28:760-770.
[153] CAPPUZZO F, MAGRINI E, CERESOLI GL, et al. AKT phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer[J]. Journal of the National Cancer Institute, 2004,96: 1133-1141.
[154] SHUKUYA T, HIRAMA M, YAE T, et al. [Efficacy of gefitinib according to smoking status in non-small cell lung cancer patients] [J]. Gan to kagaku ryoho, 2008,35:2367-2371.
[155] MATSUO K, ITO H, YATABE Y, et al. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese[J]. Cancer science, 2007,98:96-101.
[156] ITAYA T, YAMAOTO N, ANDO M, et al. Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer[J]. Cancer science, 2007,98:226-230.
[157] CLARK GM, ZBOROWSKI DM, SANTABARBARA P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21[J]. Clinical lung cancer, 2006,7:389-394.
[158]董强刚,黄进肃,杨立民,等.中国肺腺癌患者上皮生长因子受体基因突变的研究[J].肿瘤, 2006,26(3):271-275.
[159] CHAN SK, GULLICK WJ, HILL ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy[J]. Eur J Cancer, 2006,42:17-23.
[160] THATCHER N, CHANG A, PARIKH P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) [J]. Lancet, 2005,366:1527-1537.
[161] INOUE A, SAIJO Y, MAEMONDO M, et al. Severe acute interstitial pneumonia and gefitinib[J]. Lancet, 2003,361:137-139.
[162] JANNE PA, JOHNSON BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors[J]. Clin Cancer Res, 2006,12:4416s-4420s.
[163] MILLER VA, KRIS MG, SHAH N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 2004,22: 1103-1109.
[164] HAN SW, KIM TY, HWANG PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib[J]. J Clin Oncol, 2005,23: 2493-2501.
[165] TAKANO T, OHE Y, SAKAMOTO H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer[J]. J Clin Oncol, 2005,23:6829-6837.
[166] CORTES-FUNES H, GOMEZ C, ROSELL R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol, 2005,16:1081-1086.
[167] SEQUIST LV, BELL DW, LYNCH TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer[J]. J Clin Oncol, 2007,25:587-595.
[168] ICHIHARA S, TOYOOKA S, FUJIWARA Y, et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer[J]. International journal of cancer, 2007,120:1239-1247.
[169] TSAO MS, SAKURADA A, CUTZ JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome[J]. The New England journal of medicine, 2005,353: 133-144.
[170] JEON YK, SUNG SW, CHUNG JH, et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer[J]. Lung cancer (Amsterdam, Netherlands), 2006,54:387-398.
[171] DZIADZIUSZKO R, WITTA SE, CAPPUZZO F, et al. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer[J]. Clin Cancer Res, 2006,12:3078-3084.
[172] HIJIYA N, MIYAWAKI M, KAWAHARA K, et al. Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma[J]. Human pathology, 2008,39:316-323.
[173] AHRENDT SA, DECKER PA, ALAWI EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung[J]. Cancer, 2001,92:1525-1530.
[174] KIM YH, ISHII G, GOTO K, et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung[J]. Clin Cancer Res, 2004,10:7311-7317.
[175] SUZUKI M, SHIGEMATSU H, HIROSHIMA K, et al. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation[J]. Human pathology, 2005,36:1127-1134.
[176] NYATI MK, MORGAN MA, FENG FY, et al. Integration of EGFR inhibitors with radiochemotherapy[J]. Nature reviews, 2006,6:876-885.
[177] AMANN J, KALYANKRISHNA S, MASSION PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer[J]. Cancer research, 2005,65:226-235.
[178] JIANG J, GREULICH H, JANNE PA, et al. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression[J]. Cancer research,2005,65:8968-8974.
[179] RIKOVA K, GUO A, ZENG Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer[J]. Cell, 2007,131:1190-1203.
[180] GUO A, VILLEN J, KORNHAUSER J, et al. Signaling networks assembled by oncogenic EGFR and c-Met[J]. Proceedings of the National Academy of Sciences of the United States of America, 2008,105:692-697.
[181] GUHA U, CHAERKADY R, MARIMUTHU A, et al. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS[J]. Proceedings of the National Academy of Sciences of the United States of America, 2008,105:14112-14117.
[182] RAMIREZ RD, SHERIDAN S, GIRARD L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins[J]. Cancer research, 2004,64: 9027-9034.
[183] SATO M, VAUGHAN MB, GIRARD L, et al. Multiple oncogenic changes (K-RAS (V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells[J]. Cancer research, 2006,66:2116-2128.
[184] POLITI K, ZAKOWSKI MF, FAN PD, et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors[J]. Genes & development, 2006,20:1496-1510.
[185] JI H, LI D, CHEN L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies[J]. Cancer cell, 2006,9:485-495.
[186] JACKMAN DM, YEAP BY, SEQUIST LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib[J]. Clin Cancer Res,2006,12:3908-3914.
[187] RIELY GJ, PAO W, PHAM D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib[J]. Clin Cancer Res, 2006,12:839-844.
[188] BLAGOEV B, ONG SE, KRATCHMAROVA I, et al. Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics[J]. Nature biotechnology, 2004,22:1139-1145.
[189] BLAGOEV B, KRATCHMAROVA I, ONG SE, et al. A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling[J]. Nature biotechnology, 2003,21:315-318.
[190] WARD CW, GOUGH KH, RASHKE M, et al. Systematic mapping of potential binding sites for Shc and Grb2 SH2 domains on insulin receptor substrate-1 and the receptors for insulin, epidermal growth factor, platelet-derived growth factor, and fibroblast growth factor[J]. The Journal of biological chemistry, 1996,271:5603-5609.
[191] SCHULZE WX, DENG L, MANN M. Phosphotyrosine interactome of the erbB-receptor kinase family[J]. Molecular systems biology, 2005,1:2005 0008.
[192] ZHANG YW, STAAL B, SU Y, et al. Evidence that MIG-6 is a tumor-suppressor gene[J]. Oncogene, 2007,26:269-276.
[193] GANGAROSA LM, SIZEMORE N, GRAVES-DEAL R, et al. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells[J]. The Journal of biological chemistry, 1997,272: 18926-18931.
[194] STOMMEL JM, KIMMELMAN AC, YING H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies[J]. Science New York, NY, 2007,318:287-290.
[195] HUANG PH, MUKASA A, BONAVIA R, et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy forglioblastoma[J]. Proceedings of the National Academy of Sciences of the United States of America, 2007,104:12867-12872.
[196] SCHROEDER JA, ADRIANCE MC, MCCONNELL EJ, et al. erbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas[J]. The Journal of biological chemistry, 2002,277: 22692-22698.
[197] FANG D, HAWKE D, ZHENG Y, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity[J]. The Journal of biological chemistry, 2007,282:11221-11229.
[198] ABOULAICH N, VAINONEN JP, STRALFORS P, et al. Vectorial proteomics reveal targeting, phosphorylation and specific fragmentation of polymerase I and transcript release factor (PTRF) at the surface of caveolae in human adipocytes[J]. The Biochemical journal, 2004,383: 237-248.
[199] LIU L, PILCH PF. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization[J]. The Journal of biological chemistry, 2008,283:4314-4322.
[200] HILL MM, BASTIANI M, LUETTERFORST R, et al. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function[J]. Cell, 2008,132:113-124.
[201] YANG S, PARK K, TURKSON J, et al. Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression[J]. Experimental cell research, 2008,314:413-419.
[202] TICE DA, BISCARDI JS, NICKLES AL, et al. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor[J]. Proc Natl Acad Sci U S A 1999;96(4):1415-1420.
[203] LI W, MILLER WT. Role of the activation loop tyrosines in regulation of the insulin-like growth factor I receptor-tyrosine kinase[J]. J Biol Chem2006;281(33):23785-23791.
[204] BOERNER JL, DEMORY ML, SILVA C, et al. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II[J]. Mol Cell Biol 2004;24(16):7059-7071.
[205] ZHANG X, GUREASKO J, SHEN K, et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor[J]. Cell 2006;125(6):1137-1149.
[206] YANG S, QU S, PEREZ-TORES M, et al. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors[J]. Cancer Res 2006;66(14):6990-6997.
[207] CAREY KD, GARTON AJ, ROMERO MS, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib[J]. Cancer Res 2006;66(16):8163-8171.
[208] KLOTH MT, LAUGHLIN KK, BISCARDI JS, et al. STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor[J]. The Journal of biological chemistry, 2003,278:1671-1679.
[209] WITTIG I, GRONER B. Signal transducer and activator of transcription 5 (STAT5), a crucial regulator of immune and cancer cells[J]. Current drug targets, 2005,5:449-463.
[210] HUBBARD SR, WEI L, ELLIS L, et al. Crystal structure of the tyrosine kinase domain of the human insulin receptor[J]. Nature, 1994,372: 746-754.
[211] BISCARDI JS, MAA MC, TICE DA, et al. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function[J]. The Journal of biological chemistry, 1999,274:8335-8343.
[212] ROJAS M, YAO S, LIN YZ. Controlling epidermal growth factor (EGF)- stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor[J]. The Journal of biological chemistry, 1996,271:27456-27461.
[213] MITSUDOMI T, YATABE Y. Mutations of the epidermal growth factor receptor geneand related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer[J]. Cancer science, 2007,98:1817-1824.
[214] OKABE T, OKAMOTO I, TAMURA K, et al. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification[J]. Cancer research, 2007,67:2046-2053.
[215] ENDOH H, ISHIBASHI Y, YAMAKI E, et al. Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation[J]. Lung cancer (Amsterdam, Netherlands), 2009,63:241-246.
[216] NAKAMURA H, KAWASAKI N, TAGUCHI M, et al. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis[J]. Thorax, 2006,61:140-145.
[217] HIRSCH FR, VARELLA-GARCIA M, BUNN PA, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2006,24: 5034-5042.
[218] TAKEUCHI T, TOMIDA S, YATABE Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors[J]. J Clin Oncol, 2006,24:1679-1688.
[219] BELL DW, LYNCH TJ, HASERLAT SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials[J]. J Clin Oncol, 2005,23:8081-8092.
[220] EBERHARD DA, JOHNSON BE, AMLER LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib[J]. J Clin Oncol, 2005,23:5900-5909.
[221] DZIADZIUSZKO R, HIRSCH FR, VARELLA-GARCIA M, et al. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when,and how[J]? Clin Cancer Res, 2006,12:4409s-4415s.
[222] PARKIN DM. Global cancer statistics in the year 2000[J]. The lancet oncology, 2001,2:533-543.
[223] DY GK, ADJEI AA. Novel targets for lung cancer therapy: part I[J]. J Clin Oncol, 2002,20:2881-2894.
[224] BUNN PA, JR, SHEPHERD FA, et al. Ongoing and future trials of biologic therapies in lung cancer[J]. Lung cancer (Amsterdam, Netherlands), 2003,41 Suppl 1:S175-186.
[225] AZZOLI CG, KRUG LM, MILLER VA, et al. Trastuzumab in the treatment of non-small cell lung cancer[J]. Seminars in oncology, 2002,29: 59-65.
[226] SELVAGGI G, NOVELLO S, TORRI V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer[J]. Ann Oncol, 2004,15:28-32.
[227] ONN A, CORREA AM, GILCREASE M, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer[J]. Clin Cancer Res, 2004,10: 136-143.
[228]姜斌,朱冠山,刘峰,等.中国人非小细胞肺癌EGFR基因突变的研究[J].上海第二医科大学学报, 2005,25(11):1148-1150.
[229] PASTORINO U, ANDREOLA S, TAGLIABUE E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis[J]. J Clin Oncol, 1997,15:2858-2865.
[230] KURIE JM, SHIN HJ, LEE JS, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium[J]. Clin Cancer Res, 1996,2:1787-1793.
[231] RUSCH V, KLIMSTRA D, VENKATRAMAN E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression[J]. Clin Cancer Res, 1997,3:515-522.
[232] PFEIFFER P, NEXO E, BENTZEN SM, et al. Enzyme-linked immunosorbent assay ofepidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis[J]. British journal of cancer, 1998,78:96-99.
[233] SONNWEBER B, DLASKA M, SKVORTSOV S, et al. High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC) [J]. Journal of clinical pathology, 2006,59:255-259.
[234] OKAMOTO I, KENYON LC, EMLET DR, et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer[J]. Cancer science, 2003,94:50-56.
[235] KANEMATSU T, YANO S, UEHARA H, et al. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients[J]. Oncology research, 2003,13:289-298.
[236] JANNE PA, BORRAS AM, KUANG Y, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening[J]. Clin Cancer Res, 2006,12:751-758.
[237] PAN Q, PAO W, LADANYI M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas[J]. J Mol Diagn, 2005,7:396-403.
[238] NAGAI Y, MIYAZAWA H, HUQUN, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp[J]. Cancer research, 2005,65:7276-7282.
[239] ENDO K, KONISHI A, SASAKI H, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay[J]. Lung cancer (Amsterdam, Netherlands), 2005,50:375-384.
[240] YATABE Y, HIDA T, HORIO Y, et al. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer[J]. J Mol Diagn, 2006,8:335-341.
[241] NOMOTO K, TSUTA K, TAKANO T, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis[J]. American journal of clinical pathology, 2006,126:608-615.
[2] JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics, 2006. CA[J]. a cancer journal for clinicians, 2006,56:106-130.
[3] OHSAKI Y, TANNO S, FUJITA Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression[J]. Oncology reports, 2000,7: 603-607.
[4] FUJINO S, ENOKIBORI T, TEZUKA N, et al. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer[J]. Eur J Cancer, 1996,32A:2070-2074.
[5] HILBE W, DLASKA M, DIRNHOFER S, et al. Characterisation and predictive value of epidermal growth factor receptor status using quantitative real-time PCR combined with immunohistochemistry on non-small cell lung cancer specimens[J]. International journal of oncology, 2003,23:893-899.
[6] BRATTSTROM D, WESTER K, BERGQVIST M, et al. HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer[J]. Acta oncologica (Stockholm, Sweden), 2004,43:80-86.
[7] JORISSEN RN, WALKER F, POULIOT N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling[J]. Experimental cell research, 2003,284: 31-53.
[8] BASELGA J. Why the epidermal growth factor receptor? The rationale for cancer therapy[J]. The oncologist, 2002,7 Suppl 4:2-8.
[9] WOOD ER, TRUESDALE AT, MCDONALD OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells[J].Cancer research, 2004,64: 6652-6659.
[10] PAO W, MILLER VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions[J]. J Clin Oncol, 2005,23: 2556-2568.
[11] KARI C, CHAN TO, ROCHA DE QUADROS M, RODECK U. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage[J]. Cancer research, 2003,63:1-5.
[12] BASELGA J, ARTEAGA CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer[J]. J Clin Oncol, 2005,23:2445-2459.
[13] YARDEN Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities[J]. Eur J Cancer, 2001,37 Suppl 4:S3-8.
[14] MCKILLOP D, PARTRIDGE EA, KEMP JV, et al. Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor[J]. Molecular cancer therapeutics, 2005,4:641- 649.
[15] DI GENNARO E, BARBARINO M, BRUZZESE F, et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells[J]. Journal of cellular physiology, 2003,195:139-150.
[16] COHEN MH, WILLIAMS GA, SRIDHARA R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets[J]. The oncologist, 2003,8: 303-306.
[17] BISHAYEE S. Role of conformational alteration in the epidermal growth factor receptor (EGFR) function[J]. In, Biochemical pharmacology, 2000,1217-1223.
[18] RAYMOND E, LOUVET C, TOURNIGAND C, et al. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells[J]. International journal of oncology, 2002,21:361-367.
[19]李龙芸,周彩存,张国淳.非小细胞肺癌患者EGFR突变和基因扩增对吉非替尼疗效的预测价值[J].循证医学, 2006,6(1):23-27.
[20] RUOCCO S, LALLEMAND A, TOURNIER JM, et al. Expression and localization of epidermal growth factor, transforming growth factor-alpha, and localization of their common receptor in fetal human lung development[J]. Pediatric research, 1996,39: 448-455.
[21] STRANDJORD TP, CLARK JG, GURALNICK DE, et al. Immunolocalization of transforming growth factor-alpha, epidermal growth factor (EGF), and EGF-receptor in normal and injured developing human lung[J]. Pediatric research, 1995,38:851-856.
[22] FUJITA Y, KURACHI H, MORISHIGE K, et al. Decrease in epidermal growth factor receptor and its messenger ribonucleic acid levels in intrauterine growth-retarded and diabetes mellitus-complicated pregnancies[J]. The Journal of clinical endocrinology and metabolism, 1991,72:1340-1345.
[23] OGISO H, ISHITANI R, NUREKI O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains[J]. Cell, 2002,110:775-787.
[24] VERED M, BRAUNSTEIN E, BUCHNER A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin[J]. Head & neck, 2002,24:632-636.
[25] LEMOINE NR, HUGHES CM, GULLICK WJ, et al. Abnormalities of the EGF receptor system in human thyroid neoplasia[J]. International journal of cancer, 1991,49:558-561.
[26] MIETTINEN PJ, WARBURTON D, BU D, et al. Impaired lung branching morphogenesis in the absence of functional EGF receptor[J]. Developmental biology, 1997,186:224-236.
[27] KUBIAK J, MITRA MM, STEVE AR, et al. Transforming growth factor-alpha gene expression in late-gestation fetal rat lung[J]. Pediatric research, 1992,31:286-290.
[28] YASUI S, NAGAI A, OOHIRA A, et al. Effects of anti-mouse EGF antiserum on prenatal lung development in fetal mice[J]. Pediatric pulmonology, 1993,15:251-256.
[29] PLOPPER CG, ST GEORGE JA, READ LC, et al. Acceleration of alveolar type II cell differentiation in fetal rhesus monkey lung by administration of EGF[J]. The American journal of physiology, 1992,262:L313-321.
[30] PRICE LT, CHEN Y, FRANK L. Epidermal growth factor increases antioxidant enzyme and surfactant system development during hyperoxia and protects fetal rat lungs in vitro from hyperoxic toxicity[J]. Pediatric research, 1993,34:577-585.
[31] LU Z, JIANG G, BLUME-JENSEN P, et al. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase[J]. Molecular and cellular biology, 2001,21:4016-4031.
[32] JOHANNESSEN LE, RINGERIKE T, MOLNES J, et al. Epidermal growth factor receptor efficiently activates mitogen-activated protein kinase in HeLa cells and Hep2 cells conditionally defective in clathrin- dependent endocytosis[J]. Experimental cell research, 2000,260: 136-145.
[33] BERGSTROM JD, WESTERMARK B, HELDIN NE. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells[J]. Experimental cell research, 2000,259:293-299.
[34] DENNING MF, DLUGOSZ AA, CHENG C, et al. Cross-talk between epidermal growth factor receptor and protein kinase C during calcium-induced differentiation of keratinocytes[J]. Experimental dermatology, 2000, 9:192-199.
[35] ONO M, KUWANO M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs[J]. Clin Cancer Res, 2006,12:7242-7251.
[36] OLAYIOYE MA, NEVE RM, LANE HA, et al. The erbB signaling network: receptor heterodimerization in development and cancer[J]. The EMBO journal, 2000,19:3159-3167.
[37] RABEN D, HELFRICH B, BUNN PA, et al. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncologyperspective[J]. International journal of radiation oncology, biology, physics, 2004,59:27-38.
[38] LEI W, MAYOTTE JE, LEVITT ML. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells[J]. Anticancer research, 1999,19:221-228.
[39] WAKELING AE, GUY SP, WOODBURN JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy[J]. Cancer research, 2002,62: 5749-5754.
[40] SAITO Y, BERK BC. Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors[J]. Journal of molecular and cellular cardiology, 2001,33:3-7.
[41] PAEZ JG, JANNE PA, LEE JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[J]. Science (New York, NY, 2004,304:1497-1500.
[42] LYNCH TJ, BELL DW, SORDELLA R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. The New England journal of medicine, 2004,350:2129-2139.
[43] SCAGLIOTTI GV, SELVAGGI G, NOVELLO S, et al. The biology of epidermal growth factor receptor in lung cancer[J]. Clin Cancer Res, 2004,10: 4227s-4232s.
[44] RUSCH V, BASELGA J, CORDON-CARDO C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung[J]. Cancer research, 1993,53:2379-2385.
[45] CERNY T, BARNES DM, HASLETON P, et al. Expression of epidermal growth factor receptor (EGF-R) in human lung tumours[J]. British journal of cancer, 1986,54:265-269.
[46] RUSCH V, KLIMSTRA D, LINKOV I, et al. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development[J]. Cancer research,1995,55:1365-1372.
[47] REISSMANN PT, KOGA H, FIGLIN RA, et al. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer[J]. Lung Cancer Study Group. Journal of cancer research and clinical oncology, 1999,125:61-70.
[48] VOLM M, RITTGEN W, DRINGS P. Prognostic value of erbB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas[J]. British journal of cancer, 1998,77:663-669.
[49] DICKSTEIN BM, WOSIKOWSKI K, BATES SE. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor[J]. Molecular and cellular endocrinology, 1995,110:205-211.
[50] SKIMISDOTTIR S, HREGGVIDSSON GO, HOLST O, et al. A new ecological adaptation to high sulfide by a Hydrogenobacter sp[J]. growing on sulfur compounds but not on hydrogen. Microbiological research, 2001,156:41-47.
[51] HARLOZINSKA A, BAR JK, SOBANSKA E, et al. Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms[J]. Tumour Biol, 1998,19:364-373.
[52] CIARDIELLO F, BIANCO R, DAMIANO V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225[J]. Clin Cancer Res, 1999,5: 909-916.
[53] CILEDAG A, KAYA A, YETKIN O, et al. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer[J]. Tuberkuloz ve toraks, 2008,56:390-395.
[54] TSUTSUI S, OHNO S, MURAKAMI S, et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer[J]. Breast cancer research and treatment, 2002,71:67-75.
[55] JACOT W, PUJOL JL, BOHER JM, et al. Serum EGF-receptor and HER-2extracellular domains and prognosis of non-small-cell lung cancer[J]. British journal of cancer, 2004,91:430-433.
[56] CAPPUZZO F, HIRSCH FR, ROSSI E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer[J]. Journal of the National Cancer Institute, 2005,97:643-655.
[57] GAZDAR AF, SHIGEMATSU H, HERZ J, et al. Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers[J]? Trends in molecular medicine, 2004,10:481-486.
[58] MILAS I, KOMAKI R, HACHIYA T, et al. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases[J]. Clin Cancer Res, 2003,9: 1070-1076.
[59] NICHOLSON RI, GEE JM, HARPER ME. EGFR and cancer prognosis[J]. Eur J Cancer, 2001,37 Suppl 4:S9-15.
[60] BRABENDER J, DANENBERG KD, METZGER R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival[J]. Clin Cancer Res, 2001,7:1850-1855.
[61] FONTANINI G, VIGNATI S, BIGINI D, et al. Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype[J]. Eur J Cancer, 1995,31A: 178-183.
[62] CLARKE LE, LEITZEL K, SMITH J, et al. Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RT-PCR[J]. International journal of oncology, 2003,22:425-430.
[63] BLAGOSKLONNY MV. Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers[J]. Cancer biology & therapy, 2004, 3:436-440.
[64] DAS AK, CHEN BP, STORY MD, et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma[J]. Cancer research, 2007,67:5267-5274.
[65] HUMPHREY PA, GANGAROSA LM, WONG AJ, et al. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function[J]. Biochemical and biophysical research communications, 1991,178:1413-1420.
[66] MOSCATELLO DK, MONTGOMERY RB, SUNDARESHAN P, et al. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor[J]. Oncogene, 1996,13:85-96.
[67] OMIDFAR K, RASAEE MJ, MODJTAHEDI H, et al. Production and characterization of a new antibody specific for the mutant EGF receptor, EGFRvIII, in Camelus bactrianus[J]. Tumour Biol, 2004,25:179-187.
[68] MOSCATELLO DK, HOLGADO-MADRUGA M, EMLET DR, et al. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor[J]. The Journal of biological chemistry, 1998,273:200-206.
[69] OLAPADE-OLAOPA EO, MOSCATELLO DK, MACKAY EH, et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer[J]. British journal of cancer, 2000,82:186-194.
[70] SEQUIST LV. First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients[J]. J Thorac Oncol, 2008,3:S143-145.
[71] TSUCHIHASHI Z, KHAMBATA-FORD S, HANNA N, et al. Responsiveness to cetuximab without mutations in EGFR[J]. The New England journal of medicine, 2005,353:208-209.
[72] SHIGEMATSU H, LIN L, TAKAHASHI T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers[J]. Journal of the National Cancer Institute, 2005,97:339-346.
[73] REINMUTH N, JAUCH A, XU EC, et al. Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, erbB3 and VEGF in tumor samplesof lung adenocarcinoma patients[J]. Lung cancer (Amsterdam, Netherlands), 2008,62:193-201.
[74] SHARMA SV, BELL DW, SETTLEMAN J, et al. Epidermal growth factor receptor mutations in lung cancer[J]. Nature reviews, 2007,7: 169-181.
[75] GERDES AM, NIELSEN O, MOHR U, et al. Correlation between molecular genetic analyses and immunohistochemical evaluation of the epidermal growth factor receptor and p185HER2[J]. Anticancer research, 1998, 18:2529-2534.
[76] SHIGEMATSU H, TAKAHASHI T, NOMURA M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas[J]. Cancer research, 2005,65: 1642-1646.
[77] MENDELSOHN J, BASELGA J. The EGF receptor family as targets for cancer therapy[J]. Oncogene, 2000,19:6550-6565.
[78] GREULICH H, CHEN TH, FENG W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants[J]. PLoS medicine, 2005,2:e313.
[79] KALIKAKI A, KOUTSOPOULOS A, TRYPAKI M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC[J]. British journal of cancer, 2008,99:923-929.
[80] KOBAYASHI S, BOGGON TJ, DAYARAM T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib[J]. The New England journal of medicine, 2005,352:786-792.
[81] NORO R, GEMMA A, KOSAIHIRA S, et al. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of AKT without ligand stimulation[J]. BMC cancer, 2006,6:277.
[82] HOTTA K, KIURA K, TABATA M, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group[J]. Cancer journal Sudbury, Mass, 2005,11:417-424.
[83] CELLA D, HERBST RS, LYNCH TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial[J]. J Clin Oncol, 2005,23:2946-2954.
[84] KRIS MG, NATALE RB, HERBST RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial[J]. Jama, 2003,290:2149-2158.
[85] HERBST RS, MADDOX AM, ROTHENBERG ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial[J]. J Clin Oncol, 2002,20:3815-3825.
[86] RANSON M, HAMMOND LA, FERRY D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial[J]. J Clin Oncol, 2002,20:2240-2250.
[87] NAKAGAWA K, TAMURA T, NEGORO S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors[J]. Ann Oncol, 2003,14:922-930.
[88] BASELGA J, RISCHIN D, RANSON M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types[J]. J Clin Oncol, 2002,20:4292-4302.
[89] GOSS G, HIRTE H, MILLER WH, et al. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group[J]. Investigational new drugs, 2005,23:147-155.
[90] NISHIWAKI Y, YANO S, TAMURA T, et al. [Subset analysis of data in the Japanesepatients with NSCLC from IDEAL 1 study on gefitinib] [J]. Gan to kagaku ryoho, 2004,31:567-573.
[91] FUKUOKA M, YANO S, GIACCONE G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] [J]. J Clin Oncol, 2003,21:2237-2246.
[92] KITAZAKI T, FUKUDA M, SODA H, et al. Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma, two case reports[J]. Lung cancer (Amsterdam, Netherlands), 2005,49:125-128.
[93] HERBST RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients[J]. Seminars in oncology, 2003,30:30-38.
[94] LORUSSO PM, HERBST RS, RISCHIN D, et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors[J]. Clin Cancer Res, 2003,9:2040-2048.
[95] GIACCONE G, HERBST RS, MANEGOLD C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1[J]. J Clin Oncol, 2004,22:777- 784.
[96] HERBST RS, GIACCONE G, SCHILLER JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2[J]. J Clin Oncol, 2004,22:785- 794.
[97] MITSUDOMI T, KOSAKA T, YATABE Y. Biological and clinical implications of EGFR mutations in lung cancer[J]. International journal of clinical oncology / Japan Society of Clinical Oncology, 2006,11: 190-198.
[98] CUFER T, VRDOLJAK E, GAAFAR R, et al. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer[J]. Anti-cancer drugs, 2006,17:401-409.
[99] TSUBOI M, KATO H, NAGAI K, et al. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer[J]. Anti-cancer drugs, 2005,16:1123-1128.
[100] SAGARA R, KITAMI A, NAKADA T, et al. Adverse reactions to gefitinib (Iressa): revealing sycosis and pyoderma gangrenosum-like lesions[J]. International journal of dermatology, 2006,45:1002 -1003.
[101] SANDLER AB. Nondermatologic adverse events associated with anti-EGFR therapy[J]. Oncology Williston Park, NY, 2006,20:35-40.
[102] LENZ HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events[J]. Oncology Williston Park, NY, 2006,20:5-13.
[103] CERSOSIMO RJ. Gefitinib: an adverse effects profile[J]. Expert opinion on drug safety, 2006,5:469-479.
[104] FUJIWARA Y, KIURA K, TOYOOKA S, et al. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer[J]. Lung cancer (Amsterdam, Netherlands), 2006,52:99-103.
[105] GIRARD N, GERINIERE L, BLANDIN S, et al. [French experience of gefitinib in non-small cell bronchial carcinoma. [J]. Revue des maladies respiratoires, 2004,21:934-942.
[106] KANEDA H, TAMURA K, KURATA T, et al. Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer[J]. Lung cancer (Amsterdam, Netherlands), 2004,46:247-254.
[107] TAKAMOCHI K, SUZUKI K, BASHAR AH, et al. Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report[J]. Journal of medical case reports, 2007,1:138.
[108] ENDO M, JOHKOH T, KIMURA K, et al. Imaging of gefitinib-related interstitial lungdisease: multi-institutional analysis by the West Japan Thoracic Oncology Group[J]. Lung cancer (Amsterdam, Netherlands), 2006,52:135-140.
[109] TICHELAAR JW, LU W, WHITSETT JA. Conditional expression of fibroblast growth factor-7 in the developing and mature lung[J]. The Journal of biological chemistry, 2000,275:11858-11864.
[110] SORDELLA R, BELL DW, HABER DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways[J]. Science New York, NY, 2004,305: 1163-1167.
[111] SHARPLESS NE, DEPINHO RA. The INK4A/ARF locus and its two gene products[J]. Current opinion in genetics & development, 1999,9:22- 30.
[112] ROCCO JW, SIDRANSKY D. p16(MTS-1/CDKN2/INK4a) in cancer progression[J]. Experimental cell research, 2001,264:42-55.
[113] WISTUBA, II, GAZDAR AF, MINNA JD. Molecular genetics of small cell lung carcinoma[J]. Seminars in oncology, 2001,28:3-13.
[114] ONO A, YAMAMOTO N. [Advances in chemotherapy for lung cancer] [J]. Gan to kagaku ryoho, 2008,35:1475-1481.
[115] PITARCH G, GARDE J, TORRIJOS A, et al. [Adverse cutaneous reactions to erlotinib] [J]. Actas dermo-sifiliograficas, 2008,99:54-60.
[116] LACOUTURE ME, MELOSKY BL. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology- oncology perspective[J]. Skin therapy letter, 2007,12:1-5.
[117] KWAK EL, SORDELLA R, BELL DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib[J]. Proceedings of the National Academy of Sciences of the United States of America, 2005,102:7665-7670.
[118] LI T, LING YH, GOLDMAN ID, et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells[J]. Clin Cancer Res, 2007,13:3413-3422.
[119] CULLEN M. Second-line treatment options in advanced non-small cell lung cancer: current status[J]. Seminars in oncology, 2006,33:S3-8.
[120] CAPPUZZO F, LIGORIO C, JANNE PA, et al. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization- positive/phospho- AKT-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial[J]. J Clin Oncol, 2007,25:2248-2255.
[121] KIM KS, JEONG JY, KIM YC, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer[J]. Clin Cancer Res, 2005,11:2244-2251.
[122] HIRSCH FR, VARELLA-GARCIA M, BUNN PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis[J]. J Clin Oncol, 2003,21:3798-3807.
[123] SHEPHERD FA, TSAO MS. Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy[J]. J Clin Oncol, 2006,24: 1219-1220, author reply 1220-1211.
[124] KISHI K, NAKATA K, YOSHIMURA K. Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis[J]. J Thorac Oncol, 2006,1: 733-734.
[125] HAN SW, HWANG PG, CHUNG DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer[J]. International journal of cancer, 2005,113:109-115.
[126] PARRA HS, CAVINA R, LATTERI F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer[J]. British journal of cancer, 2004,91:208-212.
[127] PAO W, MILLER VA, POLITI KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain[J]. PLoS medicine, 2005,2:e73.
[128] CAPPUZZO F, GREGORC V, ROSSI E, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC[J]. J Clin Oncol, 2003,21:2658-2663.
[129] MITSUDOMI T, KOSAKA T, ENDOH H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence[J]. J Clin Oncol, 2005,23:2513-2520.
[130] MU XL, LI LY, ZHANG XT, et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer[J]. Clin Cancer Res, 2005,11:4289-4294.
[131] TARON M, ICHINOSE Y, ROSELL R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas[J]. Clin Cancer Res, 2005,11: 5878-5885.
[132] ZHU JQ, ZHONG WZ, ZHANG GC, et al. Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals[J]. Cancer letters, 2008,265:307-317.
[133] INOUE A, SUZUKI T, FUKUHARA T, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations[J]. J Clin Oncol, 2006,24:3340-3346.
[134] SUTANI A, NAGAI Y, UDAGAWA K, et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp[J]. British journal of cancer, 2006,95:1483-1489.
[135] ASAHINA H, YAMAZAKI K, KINOSHITA I, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factorreceptor mutations[J]. British journal of cancer, 2006,95:998-1004.
[136] TAMURA K, OKAMOTO I, KASHII T, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) [J]. British journal of cancer, 2008,98:907-914.
[137] KOSAKA T, YATABE Y, ENDOH H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib[J]. Clin Cancer Res, 2006,12:5764-5769.
[138] SEQUIST LV, JOSHI VA, JANNE PA, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing[J]. The oncologist, 2007,12:90-98.
[139] PAO W, MILLER V, ZAKOWSKI M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib[J]. Proceedings of the National Academy of Sciences of the United States of America, 2004,101:13306-13311.
[140] SHIMAMURA T, LI D, JI H, et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance[J]. Cancer research, 2008,68: 5827-5838.
[141] Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib[J]. Proceedings of the National Academy of Sciences of the United States of America, 2007,104: 20932-20937.
[142] INUKAI M, TOYOOKA S, ITO S, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer[J]. Cancer research, 2006,66:7854-7858.
[143] JANCARIKOVA D, PESEK M, BENESOVA L, et al. Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFRmutation T790M[J]. Anticancer research, 2007,27:1879- 1882.
[144] BELL DW, GORE I, OKIMOTO RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR[J]. Nature genetics, 2005,37:1315-1316.
[145] PAPAIAHGARI S, ZHANG Q, KLEEBERGER SR, et al. Hyperoxia stimulates an Nrf2-ARE transcriptional response via ROS-EGFR-PI3K-AKT/ERK MAP kinase signaling in pulmonary epithelial cells[J]. Antioxidants & redox signaling, 2006,8:43-52.
[146] LIU F, JIANG B, GONG SJ, et al. [Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer] [J]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 2007,24:31-34.
[147] HIRSCH FR. K-ras mutations in lung cancer: the "mysterious mutation"[J]. Clinical lung cancer, 2006,8:11-12.
[148] SUZUKI T, NAKAGAWA T, ENDO H, et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status[J]. Lung cancer (Amsterdam, Netherlands), 2003,42: 35-41.
[149] HUNCHAREK M, MUSCAT J, GESCHWIND JF. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases[J]. Carcinogenesis, 1999,20:1507-1510.
[150] PAO W, WANG TY, RIELY GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS medicine, 2005,2:e17.
[151] KOSAKA T, YATABE Y, ENDOH H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications[J]. Cancer research, 2004,64:8919-8923.
[152] GU D, SCARINGE WA, LI K, et al. Database of somatic mutations in EGFR withanalyses revealing indel hotspots but no smoking-associated signature[J]. Human mutation, 2007,28:760-770.
[153] CAPPUZZO F, MAGRINI E, CERESOLI GL, et al. AKT phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer[J]. Journal of the National Cancer Institute, 2004,96: 1133-1141.
[154] SHUKUYA T, HIRAMA M, YAE T, et al. [Efficacy of gefitinib according to smoking status in non-small cell lung cancer patients] [J]. Gan to kagaku ryoho, 2008,35:2367-2371.
[155] MATSUO K, ITO H, YATABE Y, et al. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese[J]. Cancer science, 2007,98:96-101.
[156] ITAYA T, YAMAOTO N, ANDO M, et al. Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer[J]. Cancer science, 2007,98:226-230.
[157] CLARK GM, ZBOROWSKI DM, SANTABARBARA P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21[J]. Clinical lung cancer, 2006,7:389-394.
[158]董强刚,黄进肃,杨立民,等.中国肺腺癌患者上皮生长因子受体基因突变的研究[J].肿瘤, 2006,26(3):271-275.
[159] CHAN SK, GULLICK WJ, HILL ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy[J]. Eur J Cancer, 2006,42:17-23.
[160] THATCHER N, CHANG A, PARIKH P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) [J]. Lancet, 2005,366:1527-1537.
[161] INOUE A, SAIJO Y, MAEMONDO M, et al. Severe acute interstitial pneumonia and gefitinib[J]. Lancet, 2003,361:137-139.
[162] JANNE PA, JOHNSON BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors[J]. Clin Cancer Res, 2006,12:4416s-4420s.
[163] MILLER VA, KRIS MG, SHAH N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 2004,22: 1103-1109.
[164] HAN SW, KIM TY, HWANG PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib[J]. J Clin Oncol, 2005,23: 2493-2501.
[165] TAKANO T, OHE Y, SAKAMOTO H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer[J]. J Clin Oncol, 2005,23:6829-6837.
[166] CORTES-FUNES H, GOMEZ C, ROSELL R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol, 2005,16:1081-1086.
[167] SEQUIST LV, BELL DW, LYNCH TJ, et al. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer[J]. J Clin Oncol, 2007,25:587-595.
[168] ICHIHARA S, TOYOOKA S, FUJIWARA Y, et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer[J]. International journal of cancer, 2007,120:1239-1247.
[169] TSAO MS, SAKURADA A, CUTZ JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome[J]. The New England journal of medicine, 2005,353: 133-144.
[170] JEON YK, SUNG SW, CHUNG JH, et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer[J]. Lung cancer (Amsterdam, Netherlands), 2006,54:387-398.
[171] DZIADZIUSZKO R, WITTA SE, CAPPUZZO F, et al. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer[J]. Clin Cancer Res, 2006,12:3078-3084.
[172] HIJIYA N, MIYAWAKI M, KAWAHARA K, et al. Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma[J]. Human pathology, 2008,39:316-323.
[173] AHRENDT SA, DECKER PA, ALAWI EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung[J]. Cancer, 2001,92:1525-1530.
[174] KIM YH, ISHII G, GOTO K, et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung[J]. Clin Cancer Res, 2004,10:7311-7317.
[175] SUZUKI M, SHIGEMATSU H, HIROSHIMA K, et al. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation[J]. Human pathology, 2005,36:1127-1134.
[176] NYATI MK, MORGAN MA, FENG FY, et al. Integration of EGFR inhibitors with radiochemotherapy[J]. Nature reviews, 2006,6:876-885.
[177] AMANN J, KALYANKRISHNA S, MASSION PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer[J]. Cancer research, 2005,65:226-235.
[178] JIANG J, GREULICH H, JANNE PA, et al. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression[J]. Cancer research,2005,65:8968-8974.
[179] RIKOVA K, GUO A, ZENG Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer[J]. Cell, 2007,131:1190-1203.
[180] GUO A, VILLEN J, KORNHAUSER J, et al. Signaling networks assembled by oncogenic EGFR and c-Met[J]. Proceedings of the National Academy of Sciences of the United States of America, 2008,105:692-697.
[181] GUHA U, CHAERKADY R, MARIMUTHU A, et al. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS[J]. Proceedings of the National Academy of Sciences of the United States of America, 2008,105:14112-14117.
[182] RAMIREZ RD, SHERIDAN S, GIRARD L, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins[J]. Cancer research, 2004,64: 9027-9034.
[183] SATO M, VAUGHAN MB, GIRARD L, et al. Multiple oncogenic changes (K-RAS (V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells[J]. Cancer research, 2006,66:2116-2128.
[184] POLITI K, ZAKOWSKI MF, FAN PD, et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors[J]. Genes & development, 2006,20:1496-1510.
[185] JI H, LI D, CHEN L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies[J]. Cancer cell, 2006,9:485-495.
[186] JACKMAN DM, YEAP BY, SEQUIST LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib[J]. Clin Cancer Res,2006,12:3908-3914.
[187] RIELY GJ, PAO W, PHAM D, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib[J]. Clin Cancer Res, 2006,12:839-844.
[188] BLAGOEV B, ONG SE, KRATCHMAROVA I, et al. Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics[J]. Nature biotechnology, 2004,22:1139-1145.
[189] BLAGOEV B, KRATCHMAROVA I, ONG SE, et al. A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling[J]. Nature biotechnology, 2003,21:315-318.
[190] WARD CW, GOUGH KH, RASHKE M, et al. Systematic mapping of potential binding sites for Shc and Grb2 SH2 domains on insulin receptor substrate-1 and the receptors for insulin, epidermal growth factor, platelet-derived growth factor, and fibroblast growth factor[J]. The Journal of biological chemistry, 1996,271:5603-5609.
[191] SCHULZE WX, DENG L, MANN M. Phosphotyrosine interactome of the erbB-receptor kinase family[J]. Molecular systems biology, 2005,1:2005 0008.
[192] ZHANG YW, STAAL B, SU Y, et al. Evidence that MIG-6 is a tumor-suppressor gene[J]. Oncogene, 2007,26:269-276.
[193] GANGAROSA LM, SIZEMORE N, GRAVES-DEAL R, et al. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells[J]. The Journal of biological chemistry, 1997,272: 18926-18931.
[194] STOMMEL JM, KIMMELMAN AC, YING H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies[J]. Science New York, NY, 2007,318:287-290.
[195] HUANG PH, MUKASA A, BONAVIA R, et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy forglioblastoma[J]. Proceedings of the National Academy of Sciences of the United States of America, 2007,104:12867-12872.
[196] SCHROEDER JA, ADRIANCE MC, MCCONNELL EJ, et al. erbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas[J]. The Journal of biological chemistry, 2002,277: 22692-22698.
[197] FANG D, HAWKE D, ZHENG Y, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity[J]. The Journal of biological chemistry, 2007,282:11221-11229.
[198] ABOULAICH N, VAINONEN JP, STRALFORS P, et al. Vectorial proteomics reveal targeting, phosphorylation and specific fragmentation of polymerase I and transcript release factor (PTRF) at the surface of caveolae in human adipocytes[J]. The Biochemical journal, 2004,383: 237-248.
[199] LIU L, PILCH PF. A critical role of cavin (polymerase I and transcript release factor) in caveolae formation and organization[J]. The Journal of biological chemistry, 2008,283:4314-4322.
[200] HILL MM, BASTIANI M, LUETTERFORST R, et al. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function[J]. Cell, 2008,132:113-124.
[201] YANG S, PARK K, TURKSON J, et al. Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression[J]. Experimental cell research, 2008,314:413-419.
[202] TICE DA, BISCARDI JS, NICKLES AL, et al. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor[J]. Proc Natl Acad Sci U S A 1999;96(4):1415-1420.
[203] LI W, MILLER WT. Role of the activation loop tyrosines in regulation of the insulin-like growth factor I receptor-tyrosine kinase[J]. J Biol Chem2006;281(33):23785-23791.
[204] BOERNER JL, DEMORY ML, SILVA C, et al. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II[J]. Mol Cell Biol 2004;24(16):7059-7071.
[205] ZHANG X, GUREASKO J, SHEN K, et al. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor[J]. Cell 2006;125(6):1137-1149.
[206] YANG S, QU S, PEREZ-TORES M, et al. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors[J]. Cancer Res 2006;66(14):6990-6997.
[207] CAREY KD, GARTON AJ, ROMERO MS, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib[J]. Cancer Res 2006;66(16):8163-8171.
[208] KLOTH MT, LAUGHLIN KK, BISCARDI JS, et al. STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor[J]. The Journal of biological chemistry, 2003,278:1671-1679.
[209] WITTIG I, GRONER B. Signal transducer and activator of transcription 5 (STAT5), a crucial regulator of immune and cancer cells[J]. Current drug targets, 2005,5:449-463.
[210] HUBBARD SR, WEI L, ELLIS L, et al. Crystal structure of the tyrosine kinase domain of the human insulin receptor[J]. Nature, 1994,372: 746-754.
[211] BISCARDI JS, MAA MC, TICE DA, et al. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function[J]. The Journal of biological chemistry, 1999,274:8335-8343.
[212] ROJAS M, YAO S, LIN YZ. Controlling epidermal growth factor (EGF)- stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor[J]. The Journal of biological chemistry, 1996,271:27456-27461.
[213] MITSUDOMI T, YATABE Y. Mutations of the epidermal growth factor receptor geneand related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer[J]. Cancer science, 2007,98:1817-1824.
[214] OKABE T, OKAMOTO I, TAMURA K, et al. Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification[J]. Cancer research, 2007,67:2046-2053.
[215] ENDOH H, ISHIBASHI Y, YAMAKI E, et al. Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation[J]. Lung cancer (Amsterdam, Netherlands), 2009,63:241-246.
[216] NAKAMURA H, KAWASAKI N, TAGUCHI M, et al. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis[J]. Thorax, 2006,61:140-145.
[217] HIRSCH FR, VARELLA-GARCIA M, BUNN PA, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer[J]. J Clin Oncol, 2006,24: 5034-5042.
[218] TAKEUCHI T, TOMIDA S, YATABE Y, et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors[J]. J Clin Oncol, 2006,24:1679-1688.
[219] BELL DW, LYNCH TJ, HASERLAT SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials[J]. J Clin Oncol, 2005,23:8081-8092.
[220] EBERHARD DA, JOHNSON BE, AMLER LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib[J]. J Clin Oncol, 2005,23:5900-5909.
[221] DZIADZIUSZKO R, HIRSCH FR, VARELLA-GARCIA M, et al. Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization--why, when,and how[J]? Clin Cancer Res, 2006,12:4409s-4415s.
[222] PARKIN DM. Global cancer statistics in the year 2000[J]. The lancet oncology, 2001,2:533-543.
[223] DY GK, ADJEI AA. Novel targets for lung cancer therapy: part I[J]. J Clin Oncol, 2002,20:2881-2894.
[224] BUNN PA, JR, SHEPHERD FA, et al. Ongoing and future trials of biologic therapies in lung cancer[J]. Lung cancer (Amsterdam, Netherlands), 2003,41 Suppl 1:S175-186.
[225] AZZOLI CG, KRUG LM, MILLER VA, et al. Trastuzumab in the treatment of non-small cell lung cancer[J]. Seminars in oncology, 2002,29: 59-65.
[226] SELVAGGI G, NOVELLO S, TORRI V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer[J]. Ann Oncol, 2004,15:28-32.
[227] ONN A, CORREA AM, GILCREASE M, et al. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer[J]. Clin Cancer Res, 2004,10: 136-143.
[228]姜斌,朱冠山,刘峰,等.中国人非小细胞肺癌EGFR基因突变的研究[J].上海第二医科大学学报, 2005,25(11):1148-1150.
[229] PASTORINO U, ANDREOLA S, TAGLIABUE E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis[J]. J Clin Oncol, 1997,15:2858-2865.
[230] KURIE JM, SHIN HJ, LEE JS, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium[J]. Clin Cancer Res, 1996,2:1787-1793.
[231] RUSCH V, KLIMSTRA D, VENKATRAMAN E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression[J]. Clin Cancer Res, 1997,3:515-522.
[232] PFEIFFER P, NEXO E, BENTZEN SM, et al. Enzyme-linked immunosorbent assay ofepidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis[J]. British journal of cancer, 1998,78:96-99.
[233] SONNWEBER B, DLASKA M, SKVORTSOV S, et al. High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC) [J]. Journal of clinical pathology, 2006,59:255-259.
[234] OKAMOTO I, KENYON LC, EMLET DR, et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer[J]. Cancer science, 2003,94:50-56.
[235] KANEMATSU T, YANO S, UEHARA H, et al. Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients[J]. Oncology research, 2003,13:289-298.
[236] JANNE PA, BORRAS AM, KUANG Y, et al. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening[J]. Clin Cancer Res, 2006,12:751-758.
[237] PAN Q, PAO W, LADANYI M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas[J]. J Mol Diagn, 2005,7:396-403.
[238] NAGAI Y, MIYAZAWA H, HUQUN, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp[J]. Cancer research, 2005,65:7276-7282.
[239] ENDO K, KONISHI A, SASAKI H, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay[J]. Lung cancer (Amsterdam, Netherlands), 2005,50:375-384.
[240] YATABE Y, HIDA T, HORIO Y, et al. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer[J]. J Mol Diagn, 2006,8:335-341.
[241] NOMOTO K, TSUTA K, TAKANO T, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis[J]. American journal of clinical pathology, 2006,126:608-615.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |